Understanding Our Market
MARKET SIZE
Recent studies indicate that the global economic burden attributed to Alzheimer’s Disease (AD) alone will surpass $2 trillion in the next 15-20 years. Unfortunately, studies also cite the likelihood that the incidence rate of AD, the most feared disease in the world, is going to increase rapidly.
Why?
1. The newly-discovered link between previous COVID-19 infection and an increase in Alzheimer’s cases;
2. The relationship of Alzheimer’s Disease to “Diabetes Type 3”; and
3. The aging U.S. population. Baby boomers, now numbering close to 70 million, are the country’s second-largest population group.
ABOUT THE MARKET
On the economic side, the country's overall spending on healthcare is expected to grow over 5% per year between now and 2031-- at which time it will comprise around 20% of the entire economy. If there was ever a time to seek new ways to restore homeostasis and, thereby, combat persistent and costly conditions, it is now.
NeoHack Life Sciences’ promising research into phytomedicines and potential AD preventatives – yes, preventatives - could have a huge positive impact on lessening the economic burden in the future and, more importantly, on saving lives.
Our goal is to develop an affordable remedy, potentially costing patients around $50 per month, that would establish a revenue stream of $600 million annually per million users seeking to avoid Alzheimer’s Disease. The future is both exciting and promising for NeoHack Life Sciences.
THE OPPORTUNITY
Every medical condition can be traced back to failure at some point in the homeostatic control system, whether it be in the inability to detect the initial external change, failure of initiating a feedback loop, failure to enact a response to return to the setpoint, or failure in the setpoint itself. The goal of next generation treatments must be to re-stabilize the internal milieu of the body without causing further harm and to do so promptly to avoid the death of cells from apoptosis, and irreparable failure of organ systems. (NIH)
Phytomedicine research currently underway at NeoHack Life Sciences may be exactly what leads to those next-generation treatments.